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6/j.bNatural killer (NK) cells differentiated from hematopoietic stem cells (HSCs) may have significant clinical
benefits over NK cells from adult donors, including the ability to choose alloreactive donors and potentially
more robust in vivo expansion. Stromal-based methods have been used to study the differentiation of NK
cells from HSCs. Stroma and cytokines support NK cell differentiation, but may face considerable regulatory
hurdles. A recently reported clinical-grade, heparin-based method could serve as an alternative. How the
stromal-based and heparin-based approaches compare in terms of NK cell generating efficiency or function
is unknown. We show that compared with heparin-based cultures, stroma significantly increases the yield of
HSC-derived NK cells by differentiating less-committed progenitors into the NK lineage. NK cells generated
by both approaches were similar for most NK-activating and -inhibiting receptors. Although both approaches
resulted in a phenotype consistent with CD56bright stage IV NK cells, heparin-based cultures favored the de-
velopment of CD561CD161 cells, whereas stroma produced more NK cell immunoglobulin-like receptor–
expressing NK cells, both of which are markers of terminal maturation. At day 21, stromal-based cultures
demonstrated significantly more IL-22 production, and both methods yielded similar amounts of IFN-g pro-
duction and cytotoxicity by day 35. These findings suggest that heparin-based cultures are an effective re-
placement for stroma and may facilitate clinical trials testing HSC-derived NK cells.
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After allogeneic hematopoietic cell transplantation
(allo-HCT), natural killer (NK) cells recover rapidly
and represent the predominant lymphocyte subset in
the peripheral blood (PB) over the first few months
[1-3]. Because of this, NK cells have been implicated
in graft-versus-leukemia (GVL) reactions. Accordingly,
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bmt.2011.11.023with lower rates of leukemia relapse and improved
disease-free survival [4-10].
Understanding the interaction betweenNKcell re-
ceptors and their ligands can lead to the therapeutic ex-
ploitationofNKcells.One area of intense investigation
has focusedon the killer cell immunoglobulin receptors
(KIRs) and their ligands (ie,MHCclass I). There are up
to 14 expressed KIR genes and 2 additional pseudo-
genes, which mediate both inhibitory and activation
signals. Inhibitory KIRs recognize polymorphisms of
HLA-C and -B in a biallelic manner (ie, C1 versus C2
and Bw4 versus Bw6). Based on this, NK cells from
some allo-HCT donors might not be restrained by re-
cipient MHC I. These ‘‘alloreactive’’ NK cells have
been identified in the blood of recipients early after
transplantation [11,12], and some retrospective
studies have shown that transplants from KIR ligand-
mismatched donors are associated with lower rates of
leukemia relapse [13-15]. However, the frequency of
KIR ligand-mismatched donors is relatively low
(10%-30%), with variations depending on the model
used to predict alloreactivity.
Some previous allo-HCT studies have linked the
number of KIR genes in the donor to GVL reactions.
Biol Blood Marrow Transplant 18:536-545, 2012 537Heparin versus Stroma for HSC-Derived NK CellsIndividuals differ in genomic KIR gene content, and
there are 2 main KIR haplotypes [16]. The group A
haplotype comprises 6 KIR genes, including 4 inhibit-
ing KIRs, 1 activating KIR, and 1 structurally diver-
gent KIR. In contrast, group B contains up to 12
genes, with numerous combinations of activating and
inhibitory KIR genes [17]. Patients with acute myelog-
enous leukemia (AML) who received allo-HCT from
a homozygous KIR B haplotype donor were found to
have significantly less leukemia relapse [18]. In a previ-
ous study, we determined that KIR B haplotype donors
who were homozygous for genes in the centromeric
region of KIR (Cen B/B), had the lowest relapse risk
[19]. Unfortunately, these individuals accounted for
only 10% of the donor population, and most patients
will not have a CenB/B donor available.
NK cells also can be used as cellular therapy inde-
pendent of allo-HCT.We previously tested a regimen
of high-dose chemotherapy followed by haploidentical
NK cell infusion to treat chemotherapy-refractory
AML, which resulted in a 30% remission rate [20]. In-
terestingly, remission induction was correlated with
in vivo donor NK cell expansion [20]. Rubnitz et al.
[21] reported that haploidentical NK cell infusions in
a consolidative approach were safe and potentially effi-
cacious in children receiving standard AML chemo-
therapy. They also detected donor-derived NK cells
shortly after infusion. Nontransplantation approaches
may be more appealing because of their lower toxicity,
lack of graft-versus-host disease, shorter hospitaliza-
tions, and overall simplicity.
Although NK cell therapy may be a promising
treatment approach, a number of obstacles exist. Based
on genetics (Cen B/B or KIR-L mismatch), donor NK
cells differ in their ability to mediate GVL reactions,
and the majority of patients will not have the optimal
NK donor available [19,21]. One approach to
overcoming this problem might be the use of
umbilical cord blood (UCB) units, with CD341 cells
isolated and differentiated into NK cells in vitro. We
have used a combination of cytokines and a murine
fetal liver line to study NK cell development [22-27].
Under those conditions, the majority of cells that
expand are NK cells (.85%). These cells have
a relatively immature phenotype (ie, CD56bright),
which might be desirable because they have more
proliferative capacity and could potentially persist
and function for longer periods in the recipient.
Althoughthis stromal-based system is robust, theuse
of a murine cell line may require significant regulatory
oversight. Alternative, good manufacturing practices
(GMP)-compliant methods are needed. Recently,
Spanholtz and coworkers [28,29] published a GMP-
compliant approach, known as the Glycostem NK-
expansion method, which uses a phased addition of
cytokines in a heparin-based media. Heparin binds
cytokines, reducing their degradation and perhaps pre-senting them in a more physiological manner [30-33].
In the present study, we compared stromal-based and
heparin-based methods for generating hematopoietic
stem cells (HSC)-derived NK cells. We evaluated each
approach for its ability to induce NK cell differentiation
fromHSCs, expansion, and developmental progression.
We also tested the functional capability (ie, cytotoxicity
and cytokine production) ofHSC-derivedNKcells.Our
results demonstrate that stromal-supported cultures
have a more robust expansion, but that heparin-
supported cultures give rise to an equally functional
population of cells that can be used therapeutically.METHODS
Isolation of CD341 Cells from UCB and CD561
Cells from PB
CD341 progenitor cells were isolated from freshly
isolated UCB (from New York Blood Center, New
York, NY) using magnetic bead selection (Miltenyi
Biotech, Auburn, CA). In some experiments, CD341
progenitor cells were isolated and then cryopreserved
for later use. In both cases, elected cells were routinely
.90% pure. Where specified, enriched CD341 cells
were sorted by fluorescence-activated cell sorting
(FACS) into CD341NKlin2 cells (lineage markers
CD7, CD45RA, CD161, CD122, and integrin b7),
as described previously [24]. CD561 cells were iso-
lated from PB using the Rosette separation method
and lymphocyte separation media procedure (Stem
Cells, Vancouver, Canada).
Culture of Stromal Cell Line EL08.1D2
The embryonic liver cell line EL08.1D2 was cul-
tured as described previously [25]. In brief, cells were
cultured on gelatinized plates at 32C in 40.5%
a-MEM (Invitrogen, Carlsbad, CA), 50% myelocult
(M5300; Stem Cell Technologies), and 7.5% FBS,
with b-mercaptoethanol (50 mM/L), glutamax (2
mM), penicillin (100 U/mL)/streptomycin (100 U/
mL), and hydrocortisone (1026 M). The EL08.1D2
cells were irradiated (3000 rads) before coculturing
with progenitor cells.
NK Cell Differentiation Cultures
We used 2 different techniques to generate HSC-
derived NK cells. In the stromal-based cultures [25],
CD341 cells (500 per well) were plated in a 24-well
plate on an irradiated confluent monolayer of
EL08.1D2 cells in Ham F12 plus DMEM (1:2 ratio)
with 20% male human AB2 sera (Sera Care Life Sci-
ences,Oceanside,CA), ethanolamine (50mM), ascorbic
acid (20 mg/L), 5 mg/L sodium selenite (Na2SeO3),
b-mercaptoethanol (24 mM), and penicillin (100 U/
mL)/streptomycin (100U/mL). At the start of cultures,
IL-3 (5 ng/mL), IL-7 (20 ng/mL), IL-15 (10 ng/mL),
538 Biol Blood Marrow Transplant 18:536-545, 2012S. A. Dezell et al.stem cell factor (20 ng/mL), and Flt-3L (10 ng/mL)
were added (all from R&D Systems, Minneapolis,
MN). Cultures were refreshed by demi-depletion
(50% volume change) supplemented with all of the
aforementioned cytokines except IL-3. In the
heparin-based cultures, CD341 cells (50,000 per well)
were plated in a 24-well plate [29]. Glycostem expan-
sion medium I (Glycostem, Nijmegen, the Nether-
lands) was used from days 0 to 8, Glycostem
expansion medium II was used from day 9 to day 13,
and Glycostem differentiation medium was used from
day 14 to day 35. Media changes were performed
through complete cell extraction and centrifugation
with media removal, followed by addition of the
appropriate new media and plating into new wells.
Both cell culture conditions were refreshed at the
same time and transferred to appropriate well sizes to
accommodate increased cell numbers. Cell numbers
below 200,000 were maintained in 24-well plates,
and those above 200,000 were transferred to 6-well
plates.
NK Cell Precursor Experiments
CD341 progenitor cells or specified subsets
were plated at 100 cells per well, 2 replicates per
dilution [24]. Stroma-supported conditions included
the aforementioned media and cytokines with
stroma (EL08.1D2) and with hydrocortisone
(HDC) (1026M). Heparin conditions contained the
GBGM media (Glycostem) only without stroma
and HDC. Control conditions contained previously
described media with cytokines only and without
stroma HDC. After 5 weeks, NK cell fold expansion
was measured, and flow cytometry was performed.
FACS Staining and Monoclonal Antibodies
The following antibodies were used: CD7-FITC,
CD16 (FITC or PE), CD34 (PercpCy5.5, PE, and
APC), CD56 (PercpCy5.5 or Cy7), CD94-FITC,
CD117 (PE or PercpCy5.5), CD161 (FITC or PE),
CD158a-PE, and CD158b-PE (all from BD Biosci-
ences, San Jose, CA). Additional antibodies included
NKG2D-PE (R&D Systems) and NKp30-PE,
NKp44-PE, and NKp46-PE (all from Beckman Coul-
ter, Hialeah, FL). Intracellular staining for IL-22–PE
and IFN-g–PE was performed using Cytofix/Cyto-
perm (BDBiosciences). IFN-g staining was performed
after 16 hours of stimulation with IL-12 (10 ng/mL)
and IL-18 (100 ng/mL). IL-22 staining was performed
after 16 hours of stimulation with IL-1b (10 ng/mL)
and IL-23 (10 ng/mL). Brefeldin A was added for the
last 4 hours for intracellular cytokine staining.
FACS Analysis and FACS Sorting
Three-color to 5-color FACS was performed on
a FACSCanto analyzer (BD Biosciences). Data wereanalyzed using FlowJo version 7.6.1 (Tree Star,
Ashland, OR). FACS sorting was performed on either
a FACSVantage or FACSAria cell sorter (BD Biosci-
ences).IL-22 and IFN-g Production ELISA Assays
IL-22 and IFN-g production was measured using
the DuoSet ELISA Development System (R&D Sys-
tems). Between 0.1 and 0.2 106 cells/mLwere seeded
in a 96-well plate with 100-200 uL per well of the
appropriate conditions and IL-22 stimulatory cyto-
kines IL-1b and IL-23, or IFN-g stimulatory cyto-
kines IL-12 and IL-18. Wells were labeled based on
donor and condition number. There were 3 replicates
with stimulatory cytokines and 3 without stimulatory
cytokines for control purposes. The plates were incu-
bated overnight and analyzed the next day.51Cr Release Assay
K562, Daudi, and Raji targets were labeled with
51Cr (Dupont NEN, Boston, MA) by incubating 1 
106 cells in 11.1 MBq (300 mCi) 51Cr for 2 hours at
37C in 5%CO2. The cells were washed with PBS, re-
suspended in RPMI with 10% FBS, and plated in 96-
well plates at 1  104 cells/well in triplicate. Effector
cells were added at specified ratios (between 10:1 and
2.5:1) and incubated for 4 hours at 37C in 5% CO2.
Supernatants were collected and counted (Wizard
1470; Perkin-Elmer, Shelton, CT). Specific 51Cr lysis
was calculated using the following equation:% specific
lysis 5 100  (test release – spontaneous release)/
(maximal release – spontaneous release).Statistical Analysis
Statistical analyses comparing the differences be-
tween heparin-derived NK cells and stromal-
supported cells were performed using the Student t
test for the following parameters: number of mononu-
clear cells, number of NK cells, surface phenotype,
cytotoxicity, and cytokine production (IL-22 and
IFN-g). Analysis of variance was used to determine
significant relationships between the number of NK
cells generated from CD341NKlin2 progenitors cul-
tured in stroma, those cultured in Glycostem media,
and controls. Timed analysis was calculated using
amixed model from PROCMIXED for repeatedmea-
sures and used to examine the affect of heparin versus
stroma on the absolute numbers of CD561 cells and
stage III and IV NK cells over 4 weeks [34]. This
model incorporated all data and took into account
time, the matched pairs, and the primary comparison,
as well as the interaction of the 2 factors. The F test was
used to calculate P values. A P value of\.05 was con-
sidered statistically significant for all tests.
AB
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Kinetics of Cell Expansion and CD561 NK Cell
Development
Wecompared a stromal-based approach and a hep-
arin-based approach in terms of the ability to support
overall cell expansion and generation of HSC-derived
NK cells. We did so using UCB-derived HSCs under
conditions reported previously for the 2 methods
[24,28,29]. Analyzing the total cell expansion at day
35 (D35) of culture revealed 64-fold greater total cell
expansion with the stromal-based approach compared
with the heparin-based approach (P 5 .001; n 5 22
paired donors) (Figure 1A). We then evaluated the ki-
netics of NK cell development. At D14, there were
equal percentages of NK cells in both conditions, and
over the subsequent culture period (D21-D35), a pro-
gressive increase in NK cell number was noted for
both conditions. Higher percentages of CD561 cells
were consistently observed at the early time points
(D21-D28) for stromal-based cultures (range, D14-
D35;P5 .001; n5 22 paired donors) (Figure 1B); how-
ever, byD35, the vast majority of cells wereNK cells in
both conditions, with no significant difference in the
percentage ofNK cells. Importantly, T cells do not de-
velop in these cultures [25] (data not shown). Compar-
ing the absolute number of NK cells generated in the 2
conditions showed that the stromal-based method re-
sulted in significantly more NK cells at D35 (P 5
.0002; n 5 22 paired donors) (Figure 1C); however,
the difference in the absolute number of NK cells gen-
erated by the 2methods decreased over D14-D28 (P5
.003) (Figure 1C). Collectively, these findings indicate
that the 2 approaches differ in the rate of CD561 cell
development from HSCs, but both are capable of sub-
stantial NK cell expansion by D35.Figure 1. The stromal-based approach provided higher absolute NK
cell counts than the heparin-based approach. (A) The stromal-based ap-
proach increased total cell fold expansion by 64-fold compared with the
heparin method (P 5 .001; n 5 22 paired donors). (B) CD561 expres-
sion on D14-D35 for the 2 approaches (P5.001; n5 22 paired donors).
Focusing on D21, the stromal-based approach increased CD561 ex-
pression 2-fold compared with the heparin-based approach (P 5 .001;
n 5 15 paired donors. (C) The difference in the absolute number of
NK cells generated by the 2 approaches decreased between D14 and
D28 (P 5 .003).NK Maturational Status: Comparing Stage III
and Stage IV NK Cells
NKcells progress through a series of orderly devel-
opmental steps, designated as NK stages I-V [35]. We
and others have used CD117 and CD94 expression to
distinguish human stage III and IV NK cells [25,35].
We studied the kinetics of NK cell maturation with
the 2 approaches by FACS analysis, using antibodies
directed against these antigens. Figure 2A shows
CD561-gated samples from a representative donor
for CD1171 and CD941 expression. In both ap-
proaches, the percentage of NK cells expressing
CD117 decreased progressively over time as CD94 is
acquired, consistent with the stage III/IV NK pro-
genitor transition. The heparin-based approach
tended to maintain high percentages of stage III cells
for longer periods and to demonstrate corresponding
slower CD94 acquisition at D28 (49% 6 15% versus
70%6 18%;P5 .001; n5 13). AtD35, the percentageof stage IV NK cells did not differ with the 2 ap-
proaches (67% 6 20% versus 62% 6 20%; P 5 .30;
n 5 22). Because overall mononuclear cell and NK
cell expansion was greater with the stromal-based ap-
proach (Figure 1A and B), the absolute numbers of
both stage III and IV NK cells were also greater at
D35 with the stromal-based approach (2,324,937 6
2,330,543 versus 601,253 6 877,129; P 5 .002 and
4,587,049 6 2,996,539 versus 1,562,148 6
2,624,943; P5 .0007, respectively) (Figure 2B and C).
Figure 2. Differences in CD117 and CD94 expression between the stromal-based and heparin-based approaches. (A) Sample flow cytometry data for
CD117 and CD94 expression over a 35-day period for the 2 approaches for a representative donor (CD117 on D35: P 5 .50, n 5 22 paired donors;
CD94 onD35: P5.30, n5 22 paired donors). (B) The absolute number of stage III NK cells was greatest at D35 in the stromal-based method (2,324,937
6 2,330,543 versus 601,253 6 877,129; P 5 .002). (C) The absolute numbers of stage IV NK cells was greatest at D35 in the stromal-based method
(4,587,049 6 2,996,539 versus 1,562,148 6 2,624,943; P 5 .0007).
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on HSC-Derived NK Cells
NK cell–mediated cytotoxicity is dictated by the
expression of both inhibitory and activating receptors
that can engage ligands on the surface of potential tar-
get cells. The expression of these receptors is in part de-
velopmentally controlled [35]. Given the different
kinetics of NK cell development in the 2 approaches,
we interrogated the expression of keyNKcell receptors
at D35 of culture to determine whether the 2 ap-
proaches yielded NK cells of differing receptor
expression. Expression of the activating receptors
NKp30, NKp44, NKp46, and 2B4 did not differ
between the2 approaches. Inboth approaches, these re-
ceptors were detected on nearly 100% of cells at a sim-
ilar mean fluorescence intensity (MFI) (Supplemental
Figure 1; n 5 18). Slight differences in NKG2D and
CD161 MFI were detected between the 2 methods,
with in a 1.1-fold higher MFI for NKG2D with the
stromal-based approach and a 1.5-fold higher MFIfor CD161 with the heparin-based approach (P 5 .04,
n5 18 and P5 .0001, n 5 14, respectively).
The 2 receptors demonstrating the greatest differ-
ences in percent expression were KIR and CD16, both
of which are associated with terminal maturation. At
D35, 3.4-fold more KIR-expressing NK cells were
detected in the stromal-containing cultures compared
with the heparin-containing cultures (P5 .001, n5 19
paired donors) (Figure 3A and B). Interestingly, the op-
posite was true for CD16, with 10-fold more CD161-
expressing NK cells in the heparin-based cultures (P 5
.001, n5 14 paired donors) (Figure 3C and D).
Functional Properties of HSC-DerivedNKCells:
Killing and Cytokine Production
Cytotoxicity is a hallmark measurement of NK
cell functionality andmaturational status. AtD35, cells
derived from the 2 approaches were used in killing
assays against NK-sensitive and NK-resistant targets
(K562, Raji, and Daudi cell lines). As a control,
Figure 3. KIR and CD16 receptor expression differ between the stromal-based and heparin-based methods. (A) A representative paired flow sample
displaying CD56 by KIR for a control, the heparin-based method, and the stromal-based method. (B) Summary data showing that the stromal-based
method leads to an average 3.4-fold greater KIR expression compared with the heparin-based method (P 5 .001; n5 19 paired donors). (C) A repre-
sentative paired flow sample displaying CD56 by CD16 for a control, the heparin-based method, and the stromal-based method. (D) Data showing that
the heparin-based method leads to an average 10-fold greater CD16 expression than the stromal-based method (P 5 .001; n 5 14 paired donors).
Biol Blood Marrow Transplant 18:536-545, 2012 541Heparin versus Stroma for HSC-Derived NK CellsIL-15–activated PB NK cells were included as well.
Similar cytotoxicity for the K562, Raji, and Daudi
cell lines was observed for the 2 approaches
(Figure 4A-C). Thus, both approaches resulted in
a population of equally cytotoxic NK cells.
Recent studies have demonstrated that some of the
cells that fall within the stage III NK progenitor phe-
notype (CD561/2CD117highCD942) elaborate IL-22
on stimulation with inflammatory cytokines, such as
IL-1b and IL-23 [22,36-39]. These cells have been
designated as NK22 cells, lymphoid tissue inducer–
like cells, or innate lymphoid cells [40]. Our laboratory
has recently shown that some HSC-derived stage III
CD561CD1171CD942 cells produce significant
amounts of IL-22 [22], which peaks at D21 of culture.
Given the higher percentage of stage III NK cells in
heparin-supported cultures, especially early after cul-
ture, we hypothesized that this approach would yield
more IL-22–producing cells. At D21, HSC-derived
NK cells generated with both approaches were stimu-
lated with IL-1b and IL-23, and supernatant was as-
sayed for IL-22 by ELISA. As shown in Figure 4D,
NK cells generated on stroma produced 3.5-fold
more IL-22 compared with those generated on hepa-
rin (P 5 .004; n 5 4 paired donors).
IFN-g is a key immune regulator that activates
other cells within the immune system, including
antigen-presenting cells and T cells. IFN-g isproduced by stage IV and V NK cells but not by stage
III NK cells [25], and thus its study provides an indica-
tion of the developmental and functional capabilities
of NK cells. No differences between the 2 approaches
in the percentage of intracellular IFN-g–producing
NK cells were noted after IL-12 and IL-18 stimulation
(P5 .70; n5 7 paired donors). Similar results were ob-
tained when gating on the more mature CD941 cell
fraction, which defines stage IV and V NK cells (P 5
.50; n5 7 paired donors). Examination of the quantity
of IFN-g produced found slightly higher IFN-g pro-
duction from the HSC-derived NK cells generated
on stroma compared with those derived with the hep-
arin approach (139,148 6 1,396,670 pg/mL versus
94,3096 101,033 pg/mL; P5 .06; n5 6) (Figure 4E).Differentiation of Uncommitted Progenitors to
the NK Lineage by Stroma
The UCB CD341 cell population is heteroge-
neous, and our laboratory previously found that a small
population of UCB-derived CD341 cells express re-
ceptors indicating further progression along the lym-
phoid or NK lineage, and that these cells can develop
into NK cells without stromal support [24]. These
receptors include CD7, CD45RA, CD161, CD122,
and integrin b7. This characteristic led us to name
these cells CD341NKlin1 cells. In contrast, most
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542 Biol Blood Marrow Transplant 18:536-545, 2012S. A. Dezell et al.CD341 cells (90%) do not express these receptors
(CD341NKlin2), and these progenitors require
stroma for NK development [24]. Based on the higher
NK expansion in stromal-based cultures, we hypothe-
sized that heparin-based cultures could not support the
development of CD341NKlin2 cell populations to be-
come NK cells. To test this hypothesis, we purified
CD341NKlin2 cells fromUCB and cultured them us-
ing the stroma-based and heparin-based media. Con-
trols included media and cytokines (without stroma).
NKlin2 HSCs cultured on stroma showed 7.67-fold
greater expansion (95% confidence interval [CI],
3.26-12.09) than media and 4.86-fold greater expan-
sion (95% CI, 4.5-9.28) than stromal-based cultures
(P5 .005 and .010, respectively) (Figure 5). A possible
explanation for the higher numbers of NK cells in the
stromal-based cultures could be the recruitment of
CD341NKlin2 cells to the NK lineage.Heparin Stroma Control 
0.01
0.1
1
10
L
o
g
1
0
 
F
Figure 5. Stroma recruited more NKlin2 stem cells toward NK differ-
entiation compared with heparin and control conditions. The stromal-
based approach increased NK fold expansion from NKlin2 stem cells
by an average of 6.92 units compared with the heparin-based approach
and by an average of 7.64 units compared with a corresponding control
(P5.005, n5 5, range, 1.77-12.08 and P5.010, n5 5, range, 2.48-12.79,
respectively, analysis of variance).DISCUSSION
In the present study, we compared 2 methods of
generating NK cells from HSCs in vitro. We ad-
dressed the efficiency of a heparin-based approach
and compared it with a stromal-based approach, which
is commonly considered the gold standard. We found
that total cell expansion and NK cell generation were
more robust for the stromal-based approach, but thatthe heparin-based approach could generate large
quantities of NK cells as well. Despite the significant
differences in the total cell numbers, both approaches
generated similar percentages of NK cells by D35.
HSC-derivedNK cells from both approaches had sim-
ilar levels of activating and inhibitory receptors, with
significant differences in only KIR and CD16. The 2
approaches produced a similarly mature cell product
and demonstrated similar cytotoxicity. IL-22 produc-
tion was significantly higher in stromal-based cultures,
Biol Blood Marrow Transplant 18:536-545, 2012 543Heparin versus Stroma for HSC-Derived NK Cellsbut the percentage of IFN-g–producing cells and the
total amount of IFN-g produced were similar in the
2 approaches. Thus, although the stromal cells pro-
duced more HSC-derived NK cells, classical NK cell
function was similar with the 2 approaches.
In previous work, we demonstrated the necessity
of stromal support for the differentiation of
CD341NKlin2 cells into NK cells [24]. The exact
mechanism of this support is not known, but possible
explanations include stromal cell expression of fate-
determining receptors (ie, notch and/or gas-6) and/
or elaboration of soluble factors (Wnt), cytokines, or
extracellular basement membrane (such as heparin)
[41-46].We questionedwhether the heparin-based ap-
proach also could support the differentiation of
CD341NKlin2 cells into NK cells, and found that
CD341NKlin2 cells were unable to differentiate into
significant numbers of NK cells in heparin-based cul-
tures. This observation likely explains the increased
NK cell numbers observed with the stromal-based ap-
proach, because it acts on both ‘‘NK committed’’ and
‘‘uncommitted’’ hematopoietic progenitors, whereas
the heparin-based media appears to act predominately
on the latter population. These findings also may ac-
count for the differences in IL-22 production, because
these cellsmight bederived from less-committedHSCs.
Differential expression of the receptor for the stem
cell factor (CD117) and the invariant NK cell receptor
(CD94) defines the stage III and stage IV NK cell pre-
cursors [35]. We observed a significant difference be-
tween the 2 methods with regard to the kinetics of
NK cell maturation. At D14-D28, the heparin-based
cultures showed a significant proportion of stage III
NK progenitors, whereas the stromal-based cultures
contained mainly were stage IV NK cells. Interest-
ingly, by D35, the majority of cells were stage IV cells
in both approaches. Of note, both approaches gener-
ated stage IV NK cells (CD56bright NK cells), whereas
the majority of NK cells in the PB are stage V cells
(CD56dim NK cells). Thus, additional signals, likely
through cytokines or surface receptors, were not pro-
vided in either culture. Whether or not adoptively
transferred stage IV cells have higher expansion poten-
tial in the blood of patients and, if so, whether this im-
pacts GVL reactions is unknown.
The expression of inhibitory and activating recep-
tors correlates with the maturational status and func-
tionality of the NK cell progenitors. There was little
difference in the 2 approaches for most NK receptors
tested. Perhaps the most interesting observations in-
volved KIR and CD16, both of which are correlated
with terminal differentiation. The stromal-based ap-
proach provided significantly higher amounts of KIR,
whereas the heparin-based approach yielded more
CD561CD161 cells. The mechanisms accounting for
these differences are unclear. CD16 expression by the
heparin-based cells might be attributed to granulocytecolony-stimulating factor, which leads to CD16 acqui-
sition on neutrophils [47]. Alternatively, our laboratory
previously showed that on activation, CD16 is shed
from the surface in amatrixmetaloprotease–dependent
process, and that such proteases may be expressed by
stroma cells, possibly explaining the lower CD16 ex-
pression in these conditions [48]. Such a hypothesis is
difficult to reconcile, however, given that the irradiated
stroma cells are not detectable morphologically after
2 weeks from the start of culture. Related to this
point, the number and percentage of KIR-expressing
cells was higher in the stromal cultures at D35. Thus,
it appears that the early signals (on D0-D14) provided
by stroma have a later influence onNK cell maturation
andKIRacquisition, in particular.The identity of these
signals has not yet been determined. Although few pre-
vious studies have definitively investigated the signals
that drive the stochastic expression of the KIR genes
on individual cells, 2 signals that appear to be key are
myc [49] and KIR antisense transcripts [50].
In conclusion, HSC-derived NK cells show prom-
ise in the treatment of chemotherapy-refractory malig-
nancies for their potential to create large numbers of
cells andpossibly greater in vivo expansion, and to allow
the choice of donors based on genetics. Themethodol-
ogy for generating these cells underGMP conditions is
not trivial, however. In this study, we compared
a stroma cell–based approach and a heparin-based ap-
proach. Although the stroma-supported cultures pro-
vided significantly higher numbers of NK cells, both
approaches produce remarkably similar cells with re-
spect to phenotype and function. Although superior
in terms of cell numbers, the stromal-based method
may face major obstacles with regard to Food and
Drug Administration approval and integration into
clinical trials. In contrast, the heparin-based approach
is a GMP-compliant system that can be easily adapted
into clinical trials, such as those that have demonstrated
efficacy in chemotherapy-refractory AML [20]. A re-
cent study has shown that the heparin-based product
is scalable for clinical applications using a closed biore-
actor method, yielding significant cell numbers (up to
2  109 cells) [28]. We envision a clinical trial testing
these HSC-derived NK cells in AML patients, perhaps
selecting UCB CD34 donors based on KIR ligand–
mismatched status or Cen B/B status.ACKNOWLEDGMENTS
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